

CytomX Therapeutics, Inc. Logo

CytomX to Present at the Cantor Fitzgerald Healthcare Conference

September 13, 2017 at 4:07 PM EDT

SOUTH SAN FRANCISCO, Calif., Sept. 13, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of cancer, will present at the Cantor Fitzgerald Healthcare Conference. Sean McCarthy, D.Phil., president and chief executive officer, will deliver a corporate overview on Wednesday, September 27, 2017, at 1:05 p.m. ET.

A live audio webcast of the presentation will be available through the [Investors and News section](#) of CytomX's website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage biopharmaceutical company with a deep and differentiated oncology pipeline of investigational Probody™ therapeutics. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while limiting activity in healthy tissues. The Company's pipeline includes proprietary cancer immunotherapies against clinically-validated targets, such as PD-L1, and first-in-class Probody drug conjugates against highly attractive targets, such as CD166 and CD71, which are considered to be inaccessible to conventional antibody drug conjugates due to their presence on healthy tissue. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Bristol-Myers Squibb Company, Pfizer Inc., MD Anderson Cancer Center and ImmunoGen, Inc. For more information, visit www.cytomx.com or follow us on [Twitter](#).

Media Contact:

Spectrum
Christine Quern
cquern@spectrumsience.com
202-587-2588

Investor Contact:

Trout Group
Pete Rahmer
prahmer@troutgroup.com
646-378-2973



CytomX Therapeutics Inc.